China Medical Tribune (Correspondent Zhu Fan) The Systematic Biomedical Collaborative Innovation Center led by Shanghai Jiao Tong University has joined 17 hospitals in China's Hematology / Oncology Clinical Multi-Centre Research Institute (M-HOPES), and has recently developed lymphoma Significant landmark results have been obtained in the study of principles and clinical prognosis, which fully reflects the purpose of multi-center and multi-disciplinary collaborative innovation for the benefit of patients.

a (NKTCL) is a special type of lymphoma with malignant proliferation of CD56 + / cytoCD3 + lymphocytes. The disease is closely related to Epstein-Barr virus infection. It is relatively high in Asian populations, has a dangerous incidence, and has a poor prognosis. However, the pathogenesis of this disease has not been elucidated, which has brought major challenges to find disease-specific biological markers and treatment methods and to effectively improve the efficacy of this type of lymphoma.
The Shanghai Institute of Hematology from the Center for Systematic Biomedical Collaborative Innovation has collaborated with 17 hospitals across the country to conduct genomics, molecular pathology, and clinical prognosis correlation studies on NKTCL, a hematological tumor with unique regional and clinical characteristics. Made breakthrough results in the field of precision medicine.
The research team led by Academician Chen Saijuan, Academician Chen Zhu and Professor Zhao Weilai of the Systematic Biomedical Collaborative Innovation Center used second-generation sequencing technology to perform exome sequencing on 25 cases of NKTCL. The central research institution platform has been fully validated in an expanded sample of 80 NKTCL patients.
The research results found that the RNA helicase DDX3X gene, an important gene that regulates the structure and function of RNA in cells, has high-frequency mutations in NKTCL, and its mutation rate ranks first among all gene mutations, followed by the mutation frequency of the tumor suppressor gene TP53. The sum of the mutation rates of the two genes accounted for 32.4% of all gene mutations; the mutual exclusion of DDX3X and TP53 gene mutations suggested that the pathogenic mechanism of the two was highly correlated. Protein and cell function studies show that wild-type DDX3X protein has the effect of down-regulating nuclear RelB expression and reducing cellular ERK phosphorylation levels, inhibits cell proliferation, has the characteristics of tumor suppressor gene products, and DDX3X mutations cause its encoded protein function Inactivation causes excessive cell proliferation.
The study also confirmed that DDX3X gene mutations are molecular markers of poor prognosis in patients in a large group of cases. At the same time, combined with TP53 mutations and the International Prognostic Index (IPI) of lymphoma, NKTCL patients can be further divided into 3 groups: low-risk group ( IPI index 0–1 and DDX3X and TP53 are wild type), intermediate risk group (IPI index 0–1 and DDX3X or TP53 are mutant type; IPI index 2–5 and DDX3X and TP53 are wild type) and high risk group (IPI index 2–5 and DDX3X or TP53 is mutant). These results make the stratification of clinical prognosis of NKTCL clearer and more rigorous, and provide potential targets for stratified precision treatment of the disease.
On July 20, 2015, the journal Nature Genetics reported the results of this study. This is by far the most comprehensive and systematic genomics map of NCTCL, and it is also a study of the pathogenic principles and clinical significance of related mutant genes The in-depth and systematic explanation shows that Chinese scientists have become one of the world's most popular epidemic in the field of lymphoma research and have made important contributions to the development of lymphoma translational medicine.
This research has won the National 973 Program (2013CB966800), the Twelfth Five-Year Plan for the Development of New Drugs (2013ZX09303302), the Industry Fund of the Health Planning Commission (201202003), the National Natural Science Foundation of China's Excellent National Key Laboratory Project (81123005), and the National Outstanding Youth Science Fund (81325003), etc. and the national multi-center blood / tumor collaboration system (M-HOPES).
                                                                                                                                                                                                                                     -------- Edited by Bai Youbi Sun quoted from http://www.wtoutiao.com/p/k387qW.html